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Ventricular Arrhythmias
and Sleep-Disordered
Breathing in HF PatientsWe read with interest the study by Patton et al. (1)
on the unexpected absence of typical circadian
variation of ventricular arrhythmias observed in the
SCD-HeFT (Sudden Cardiac Death in Heart Failure
Trial). Sleep-disordered breathing (SDB), broadly
categorized into obstructive and central sleep ap-
nea, has been associated with increased cardiovas-
cular morbidity and mortality. Cardiac arrhythmias
are responsible for some of the higher cardiovas-
cular morbidity and mortality rates observed in
patients with SDB. The association between atrial
ﬁbrillation and SDB is well established, although
the association between SDB and life-threatening
ventricular arrhythmias also seems plausible.
Obstructive sleep apnea predicts sudden cardiac
death independently of other well-established risk
factors (2), and, unlike the general population, pa-
tients with SDB have a higher incidence of sudden
cardiac death during sleep (3). Studies consistently
report an SDB prevalence of $50% in the chronic
heart failure population. The prevalence of SDB
in patients with an implantable cardioverter-
deﬁbrillator (ICD) ranges between 57.8% and
66.3% (4,5). In a cohort of 472 ICD patients with
heart failure receiving cardiac resynchronization
therapy, a signiﬁcant risk enhancement of ventric-
ular arrhythmias and appropriate ICD therapies
owing to both central and obstructive sleep apnea
was found (5). Importantly, for heart failure pa-
tients with a primary inappropriate ICD therapies
(4). Patton et al. (1) observed an increase in the
onset of ventricular arrhythmias during sleep in
patients with an ICD and SDB. Data on SDB for pa-
tients enrolled in the SCD-HeFT were not reported.
Thus, it is our opinion that the observed deviation
in circadian variation of ventricular arrhythmias
reported by Patton et al. (1) may be inﬂuenced, atleast in part by the presence of SDB, a very pre-
valent condition among heart failure patients with
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61–74.REPLY: Circadian Variations of Ventricular
Arrhythmias and Sleep-Disordered Breathing
in HF PatientsWe appreciate the interest of Dr. Arias and colleagues
in our study of circadian and septadian patterns of
implantable cardioverter-deﬁbrillator therapy in the
SCD-HeFT (Sudden Cardiac Death in Heart Failure
Trial) population (1). In their Letter, they relevantly
highlight the importance of sleep-disordered brea-
thing as a trigger of ventricular arrhythmias and
implantable cardioverter-deﬁbrillator therapies. Both
central and obstructive sleep apnea exert strong
effects on the autonomic nervous system and are
known to be proarrhythmic (2).
We agree with Dr. Arias and colleagues that sleep-
disordered breathing is an important and increas-
ingly recognized trigger of arrhythmias (3). Unfortu-
nately, we do not have information on the presence
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1969or absence of sleep apnea in SCD-HeFT and were
therefore unable to disentangle this likely complex
relationship. However, we note that the overall
cohort and several subgroups analyzed still showed
a typical nadir in arrhythmia therapy from 12 AM to
6 AM, which is the conventional sleep time period
with increased sudden death risk in the sleep-
disordered breathing population (4). Interestingly,
this nadir was not signiﬁcant in the nonischemic
heart failure group, the class III heart failure group,
in subjects younger than 50 years, or in the beta-
blocker group (1).
Further clinical studies to elucidate the relation-
ship between sleep-disordered breathing and ven-
tricular (and atrial) arrhythmias to design preventive
therapies will clearly be of great interest (5).*Kristen K. Patton, MD
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